{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:27:21Z","timestamp":1793842041117,"version":"4.6.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2019.05.066","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T18:42:38Z","timestamp":1560278558000},"page":"7061-7069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Purification of flavivirus VLPs by a two-step chomatographic process"],"prefix":"10.1016","volume":"37","author":[{"given":"T\u00falio M.","family":"Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus O.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5904-410X","authenticated-orcid":false,"given":"Leda R.","family":"Castilho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2019.05.066_b0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrmicro1067","article-title":"A structural perspective of the flavivirus life cycle","volume":"3","author":"Mukhopadhyay","year":"2005","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.05.066_b0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/21645515.2017.1389363","article-title":"Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination","volume":"14","author":"Kaaijk","year":"2017","journal-title":"Hum Vacc Immunotherap"},{"key":"10.1016\/j.vaccine.2019.05.066_b0015","doi-asserted-by":"crossref","first-page":"E291","DOI":"10.3390\/genes9060291","article-title":"What does the future hold for yellow fever virus?","volume":"9","author":"Klitting","year":"2018","journal-title":"Genes"},{"key":"10.1016\/j.vaccine.2019.05.066_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2016.02.006","article-title":"The Zika outbreak of the 21st century","volume":"68","author":"Changa","year":"2016","journal-title":"J Autoimmun"},{"issue":"41","key":"10.1016\/j.vaccine.2019.05.066_b0025","article-title":"Concurrent outbreaks of dengue, chikungunya and Zika virus infections \u2013 an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012\u20132014","volume":"19","author":"Roth","year":"2014","journal-title":"Euro Surveillance"},{"key":"10.1016\/j.vaccine.2019.05.066_b0030","unstructured":"PAHO\/WHO. Zika cases and congenital syndrome associated with Zika virus reported by countries and territories in the Americas, 2015\u20132018 Cumulative cases. <https:\/\/www.paho.org\/hq\/index.php?option=com_docman&view=download&category_slug=cumulative-cases-pdf-8865&alias=43296-zika-cumulative-cases-4-january-2018-296&Itemid=270&lang=en> [accessed November 06, 2018]."},{"key":"10.1016\/j.vaccine.2019.05.066_b0035","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa1602412","article-title":"Zika virus infection in pregnant women in Rio de Janeiro","volume":"375","author":"Brasil","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2019.05.066_b0040","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14712598.2017.1346081","article-title":"Current views on Zika virus vaccine development","volume":"17","author":"Barzon","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2019.05.066_b0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2017.03.001","article-title":"Zika virus: History, epidemiology, transmission, and clinical presentation","volume":"308","author":"Song","year":"2017","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.066_b0050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cll.2010.01.001","article-title":"Yellow fever: a reemerging threat","volume":"30","author":"Gardner","year":"2010","journal-title":"Clin Lab Med"},{"issue":"15","key":"10.1016\/j.vaccine.2019.05.066_b0055","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMp1702172","article-title":"Yellow fever - once again on the radar screen in the Americas","volume":"376","author":"Paules","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.05.066_b0060","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/scientificamerican0898-88","article-title":"The Philadelphia Yellow Fever Epidemic of 1793","volume":"279","author":"Foster","year":"1998","journal-title":"Sci Am"},{"issue":"4","key":"10.1016\/j.vaccine.2019.05.066_b0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.gaceta.2008.09.008","article-title":"A mortality study of the last outbreak of yellow fever in Barcelona City (Spain) in 1870","volume":"23","author":"Soler","year":"2009","journal-title":"Gac Sanit"},{"issue":"2","key":"10.1016\/j.vaccine.2019.05.066_b0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bjid.2017.02.004","article-title":"Yellow fever outbreak in Brazil, 2017","volume":"21","author":"Goldani","year":"2017","journal-title":"Braz J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2019.05.066_b0075","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S1473-3099(17)30419-X","article-title":"Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis","volume":"17","author":"Shearer","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.05.066_b0080","doi-asserted-by":"crossref","unstructured":"WHO. WHO position on the use of fractional doses - June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper - June 2013. Vaccine 2017; 35(43):5751\u20132.","DOI":"10.1016\/j.vaccine.2017.06.087"},{"issue":"2","key":"10.1016\/j.vaccine.2019.05.066_b0085","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1590\/1806-9282.64.02.106","article-title":"Yellow fever","volume":"64","author":"Litvoc","year":"2018","journal-title":"Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"},{"issue":"28","key":"10.1016\/j.vaccine.2019.05.066_b0090","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1016\/j.vaccine.2018.05.041","article-title":"Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study","volume":"36","author":"de Menezes","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.066_b0095","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijid.2016.04.025","article-title":"Yellow fever cases in Asia: primed for an epidemic","volume":"48","author":"Wasserman","year":"2016","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.066_b0100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2006.07.018","article-title":"Virus-like particles: passport to immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Methods"},{"issue":"10","key":"10.1016\/j.vaccine.2019.05.066_b0105","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Rold\u00e3o","year":"2010","journal-title":"Expert Rev Vacc"},{"issue":"2","key":"10.1016\/j.vaccine.2019.05.066_b0110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.29245\/2578-3009\/2018\/2.1118","article-title":"Advances and challenges in enveloped virus-like particle (VLP)-based vaccines","volume":"2","author":"Dai","year":"2018","journal-title":"J Immunol Sci"},{"key":"10.1016\/j.vaccine.2019.05.066_b0115","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jip.2011.05.004","article-title":"Large-scale production and purification of VLP-based vaccines","volume":"107","author":"Vicente","year":"2011","journal-title":"J Invertebr Pathol"},{"key":"10.1016\/j.vaccine.2019.05.066_b0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jviromet.2011.03.021","article-title":"Purification and concentration of non-infectious West Nile virus-like particles and infectious virions using a pseudo-affinity Cellufine Sulfate column","volume":"174","author":"Ohtaki","year":"2011","journal-title":"J Virol Methods"},{"issue":"24","key":"10.1016\/j.vaccine.2019.05.066_b0125","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.vaccine.2014.02.036","article-title":"Development of a membrane adsorber based capture step for the purification of yellow fever virus","volume":"32","author":"Pato","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.066_b0130","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1016\/j.vaccine.2019.04.077","article-title":"Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture","volume":"37","author":"Pato","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.066_b0135","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.memsci.2007.12.021","article-title":"Anion-exchange membrane chromatography for purification of rotavirus-like particles","volume":"311","author":"Vicente","year":"2008","journal-title":"J Membr Sci"},{"issue":"12","key":"10.1016\/j.vaccine.2019.05.066_b0140","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/bit.24578","article-title":"A new large-scale manufacturing platform for complex biopharmaceuticals","volume":"109","author":"Vogel","year":"2012","journal-title":"Biotechnol Bioeng"},{"issue":"5","key":"10.1016\/j.vaccine.2019.05.066_b0145","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4155\/pbp.13.49","article-title":"Virus-like particle bioprocessing: challenges and opportunities","volume":"1","author":"Middelberg","year":"2013","journal-title":"Pharmaceut Bioprocess"},{"issue":"47","key":"10.1016\/j.vaccine.2019.05.066_b0150","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1016\/j.vaccine.2019.05.064","article-title":"Zika virus-like particles (VLPs): stable cell lines and continuous perfusion processes as a new potential vaccine manufacturing platform","volume":"37","author":"Alvim","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.066_b0155","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0076-6879(82)87025-0","article-title":"Buffers of constant ionic strength for studying pH-dependent processes","volume":"87","author":"Ellis","year":"1982","journal-title":"Methods Enzymol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.05.066_b0160","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/btpr.2501","article-title":"Development of a 3-step straight-through purification strategy combining membrane adsorbers and resins","volume":"33","author":"Hughson","year":"2017","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.vaccine.2019.05.066_b0165","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.chroma.2015.12.006","article-title":"Modeling and simulation of anion-exchange membrane chromatography for purification of Sf9 insect cell-derived virus-like particles","volume":"1429","author":"Ladd Effio","year":"2016","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.vaccine.2019.05.066_b0170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.chroma.2015.11.037","article-title":"Rational development of two flowthrough purification strategies for adenovirus type 5 and retro virus-like particles","volume":"1426","author":"Nestola","year":"2015","journal-title":"J Chromatogr A"},{"issue":"4","key":"10.1016\/j.vaccine.2019.05.066_b0175","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/jam.12922","article-title":"Enterovirus71 virus-like particles produced from insect cells and purified by multistep chromatography elicit strong humoral immune responses in mice","volume":"119","author":"Zhao","year":"2015","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.vaccine.2019.05.066_b0180","series-title":"WHO Study Group on cell substrates for production of biologicals","author":"World Health Organization","year":"2007"},{"key":"10.1016\/j.vaccine.2019.05.066_b0185","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ebiom.2017.12.010","article-title":"Passive transfer of immune sera induced by a Zika virus-like particle vaccine protects AG129 mice against lethal Zika virus challenge","volume":"27","author":"Espinosa","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2019.05.066_b0190","unstructured":"Native Antigen Company (NAC). Dengue virus serotype 2 envelope protein (HEK293); 2019. <https:\/\/thenativeantigencompany.com\/products\/dengue-virus-serotype-2-envelope-protein\/> [accessed April 30, 2019]."},{"key":"10.1016\/j.vaccine.2019.05.066_b0195","unstructured":"Native Antigen Company (NAC). Zika Virus VLP \u2013 Certificate of Analysis; 2019. <https:\/\/thenativeantigencompany.com\/wp-content\/uploads\/2018\/10\/CofA-ZIKV-VLP-100-Batch17061910-new-address.pdf> [accessed April 30, 2019]."},{"issue":"7","key":"10.1016\/j.vaccine.2019.05.066_b0200","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/jps.20377","article-title":"Stabilization of human papillomavirus virus-like particles by non-ionic surfactants","volume":"94","author":"Shi","year":"2005","journal-title":"J Pharm Sci"},{"issue":"35","key":"10.1016\/j.vaccine.2019.05.066_b0205","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1016\/j.vaccine.2015.03.078","article-title":"Aggregation and antigenicity of virus like particle in salt solution - A case study with hepatitis B surface antigen","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:36:10Z","timestamp":1759401370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19307030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":41,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X19307030"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.066","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Purification of flavivirus VLPs by a two-step chomatographic process","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}